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ABSTRACT
The development and clinical use of antimicrobial agents continue to evolve in line with new science,
understanding and needs. While antimicrobial resistance remains an important determinant for drug
development and therapeutic choice, pharmacokinetic and pharmacodynamic parameters are having
an ever-increasing importance in deﬁning performance targets for new and established agents.
Recently licensed new therapies are largely directed at serious hospital-associated Gram-positive
infections, whereas in the community, therapeutic choice remains dependent on well-established
agents from limited classes of antimicrobials. In order to maximise the beneﬁts from such agents, it is
appropriate that dosage regimens and antibacterial choices be reviewed in the light of new
knowledge, particularly in the area of pharmacokinetics and pharmacodynamics. Antimicrobial
resistance continues to evolve, notably within respiratory pathogens, therefore steps must be taken to
maintain optimum therapeutic outcomes and also limit the development and spread of resistant
strains. Whilst changes in patient and physician attitudes and behaviour towards better quality
prescribing are important, new agents must also be developed to provide adequate coverage for
resistant pathogens. Development times for novel agents and classes of antimicrobials are long, with
uncertain safety proﬁles and chances of success. Thus, the development of new formulations of
existing agents, designed to overcome current resistance patterns, constitutes a potentially important
additional strategy towards appropriate prescribing.
Keywords Drug resistance, drug development, pharmacokinetics, pharmacodynamics, antibiotic
prescribing
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INTRODUCTION
Infectious diseases are among the leading causes of
death, with respiratory disease accounting for a
high proportion of mortality world-wide (Fig. 1)
[1]. In addition to morbidity and mortality, respir-
atory tract infections (RTIs) impose a major econo-
mic burden on governments, health-care systems
and individuals. In theUK, for example, the annual
health-care costs of community-acquired pneu-
monia have been estimated as £441 million (based
on 1992–93 prices) [2]. Although a less severe
infection, sinusitis is also responsible for consider-
able health-care-associated expenditure, account-
ing for approximatelyUS$3.39 billion in theUSA in
1996 [3]. A third example of a common respiratory
illness is acute exacerbation of chronic bronchitis in
adults. In Spain, the cost of treating a single acute
exacerbation of chronic bronchitis is estimated at
US$159, rising toUS$447.50 if initial therapy fails [4].
RESPIRATORY PATHOGENS AND
RESISTANCE
The three most frequently identiﬁed bacterial
pathogens in RTIs are Streptococcus pneumoniae,
Haemophilus inﬂuenzae and Moraxella catarrhalis
[2–6]. All three of these pathogens now exhibit
resistance to commonly prescribed antimicrobials,
although resistance prevalences vary consider-
ably. There is clear evidence that resistance
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among S. pneumoniae is linked to increased mor-
bidity, treatment failures leading to prolonged
therapy, loss of productivity and, in some cases,
death [7,8]. Although the impact of resistance
among H. inﬂuenzae and M. catarrhalis remains
unclear, treatment failures leading to poor clinical
outcome and requiring additional therapy should
be avoided. In addition, the cost element associ-
ated with resistance is becoming more evident [9].
Of the three major respiratory pathogens, in-
creased resistance among S. pneumoniae is of great-
est concern. Over the decade from 1992 to 2001, the
prevalence of penicillin-resistant S. pneumoniae
(penicillin MICs ‡ 2 mg ⁄L) increased substantially
in several European countries and the USA, reach-
ing 35.8% in France, 30.2% in Spain (the highest
prevalences in the European countries studied) and
20.4% in the USA by 2001 (Figure 2) [10]. In
addition to penicillin resistance, there has been an
increase in the prevalence of resistance among
S. pneumoniae to other antimicrobials, particularly the
macrolides. Worryingly, the majority of resistant
isolates are resistant to multiple classes of antimicro-
bials. For example, in 2001, 32.7% of penicillin-
resistantS.pneumoniae inFrancewerealso resistant to
macrolides, aswere 17.0% in Spain and 15.3% in the
USA. Cross-resistance to penicillin and cotrimoxa-
zole among S. pneumoniae in 2001 was 23.6%, 29.2%
and 17.2% in France, Spain and the USA, respect-
ively [10]. Clearly, the high prevalence of multiple-
drug resistance among S. pneumoniae seen in these
countries has the potential to seriously impactmany
ﬁrst-line antimicrobial therapies.
Antimicrobial resistance is important, increas-
ing and global [11]; however, the prevalence of
resistance varies greatly from country to country.
For example, in Germany and the UK, the
prevalence of penicillin-resistant S. pneumoniae
was below 2% in 2001, although intermediate
susceptibility to penicillin (MICs 0.1–1 mg ⁄L) was
6.1% and 6.0%, respectively, and the prevalence
of macrolide-nonsusceptible S. pneumoniae was
6.9% and 13.0%, respectively, in these countries
[10,12]. Micro-organisms do not observe geo-
graphic boundaries; therefore it is clear that there
must be factors speciﬁc to individual countries
that drive resistance. Foremost among these is
prescribing practice. Other factors include poor
patient compliance, differences in antimicrobial
performance and clonal spread of resistance [13].
THERAPY OPTIONS TO COMBAT
RESISTANCE
As the prevalence and level of resistance continue
to increase, new therapeutic agents are increas-
ingly required [14]. Unfortunately, very few such
agents have become available, and those that have
been developed are largely derivatives of existing
classes. Some novel agents have been introduced,
such as the oxazolidinones; however, these have
had limited therapeutic indications, with activity
restricted to penicillin-susceptible S. pneumoniae.
For the treatment of RTIs, either in the hospital
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setting or empirically in the community, new
antimicrobial classes are lacking.
The availability of novel agents and classes is
limited; therefore alternative strategies are neces-
sary to combat and contain resistance. Various
global and national organisations, including the
World Health Organisation (WHO), the US Cen-
ters for Disease Control and Prevention (CDC),
the Commission of the European Communities
(European Union) and the UK Standing Medical
Advisory Committee (SMAC) have not only
assessed the impact of resistance, but have also
suggested solutions for preventing its develop-
ment and spread (Table 1) [7,15–17]. The fol-
lowing six key elements have been identiﬁed.
(i) Surveillance of resistance enables the recogni-
tion of resistance at the national, regional and
local level as it develops, as well as tracking
changes over time, and may highlight the need for
interventions. For the purpose of guiding physi-
cian choices, high-quality surveillance data at the
local level is needed. While national studies can
identify general trends, these may not adequately
reﬂect the prevalence of resistance in different
localities, and it is the local pathogens with which
the prescribing physician in the clinic needs to be
concerned. (ii) Monitoring antimicrobial use in
conjunction with surveillance, may make evident
correlations between patterns of use and the
development of resistance. Monitoring use is an
area that has been developed somewhat bela-
tedly, but good-quality data are now becoming
available. (iii) Promotion of prudent prescribing is
a rather vague term, often associated with a
recommendation to use available antimicrobial
agents as ‘judiciously’ as possible. To do so,
however, requires sound evidence of the need to
prescribe as well as data that support suscepti-
bility of the target pathogen(s) to the agent
selected. (iv) Education of the medical profession
and the public on what constitutes appropriate
use of antimicrobials is clearly needed to minim-
ise inappropriate use, but again requires a
stronger scientiﬁc basis. (v) The importance of
hygiene in controlling hospital-acquired infections
is now well established and accepted. (vi) The
development of new agents and new vaccines
must be pursued.
Two of these key areas deserve greater atten-
tion: ‘prudent’ prescribing and the development
of new agents. In looking at the issue of prudent
prescribing, one or two deﬁnitions can be found
[7,15]. The CDC, for example, recommends
prescribing when it is likely to be beneﬁcial to
the patient [15]. ‘Beneﬁcial’ is not deﬁned and is
a somewhat nebulous term. The CDC also
recommends using an agent that targets the
likely causative pathogens [15]. ‘Likely’ is the
key word here, because most prescribing is
empiric. Lastly, the CDC encourages using a
drug at the appropriate dose and for the
appropriate duration [15]. These statements,
while reﬂecting common-sense thinking, do not
provide accurate clinical guidance in speciﬁc
indications. The WHO extends the deﬁnition
somewhat by introducing cost-effectiveness, the
need to minimise toxicity to the patient and to
minimise the development of antimicrobial
resistance [7]. It is only when all of these issues
become interwoven that one begins to see a true
deﬁnition of appropriate antimicrobial therapy
beyond the imprecise and qualitative terms
‘judicious’ and ‘prudent’.
In regard to drug development, there are three
main options available (Fig. 3). The ﬁrst is to work
towards developing a new class of antimicrobial.
Table 1. Recommendations on con-
trolling the development and spread
of antimicrobial resistance [7,15–17] Recommendation
Recommending
organisation
Raise awareness among physicians and patients WHO, CDC, EU, SMAC
Use a suitable agent for the probable
infecting pathogen
WHO, CDC, SMAC
Prescribe agents at a suitable dose
and for an appropriate duration
WHO, CDC, SMAC
Prescribe only for bacterial infections WHO, CDC, EU, SMAC
Do prescribe when antimicrobials are warranted WHO, CDC, EU, SMAC
Use drugs with the lowest possible toxicity WHO
WHO, World Health Organisation; CDC, US Centers for Disease Control and
Prevention; EU, Commission of the European Communities (European Union);
SMAC, UK Standing Medical Advisory Committee.
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Given the current status of research in this area,
however, it is likely to take considerable time
before the goal of introducing a new class of agent
into clinical use for community infection is real-
ised. Even then, the safety proﬁle of a new agent
is unlikely to be deﬁned in totality until the new
drug has been licensed and used extensively.
With regard to resistance, although it is possible
to evaluate the in-vitro resistance patterns of
pathogens in response to a new agent, the true
rate of the evolution of resistance once the drug
encounters pathogens in a host is difﬁcult to
predict reliably, as is its ability to disseminate.
The second option is to develop new agents
within existing antimicrobial classes. With this
option, key safety liabilities are, in many ways,
known. As has been seen with the ﬂuoroquino-
lones, however, there are differences in safety
proﬁles between agents within a class and it is not
entirely possible to predict these differences from
known structure–activity relationships. In devel-
oping a new agent within an existing class, the
new drug will need to be able to overcome
existing resistance, and will need to be more
potent than previous members of the class
through improvement in target site afﬁnity, sta-
bility to inactivating mechanisms or cellular
penetration, for example. The third option is to
develop a new formulation of an existing agent. In
this case, the safety proﬁle will generally be well
known. However, there remains a need to over-
come bacterial resistance against the molecule in
its currently available clinical form. This third
approach is likely to have the shortest develop-
ment time. Although this is not guaranteed,
starting from an existing agent provides an
information base that would otherwise need to
be created for a new agent or class, a process that
can be very lengthy (Fig. 3).
STANDARDS OF PERFORMANCE:
PHARMACOKINETICS AND
PHARMACODYNAMICS
The rational development of new antimicrobials,
or new formulations of existing agents, requires
that we understand what we need from these
advances. In recent years, the impact of pharma-
cokinetics (PK) and pharmacodynamics (PD) on
antimicrobial efﬁcacy has been a rich area of
research (see MacGowan, this issue). We are now
in a position where we can use PK ⁄PD parame-
ters to predict the potential of antimicrobials to
achieve bacterial eradication, particularly for cer-
tain RTI infections [18,19]. Moreover, we can use
these PK ⁄PD predictions to set targets of antibac-
terial performance that allow us to speciﬁcally
design antimicrobials with the desired proﬁle to
be effective against pathogens resistant to other
agents or clinical formulations (see Jacobs, this
issue). This supplement discusses the develop-
ment of a novel, pharmacokinetically enhanced
formulation of amoxicillin ⁄ clavulanate. Uniquely,
this formulation was designed to combat increas-
ing resistance based on PK ⁄PD targets of efﬁcacy
derived from previous work with conventional
formulations of amoxicillin ⁄ clavulanate. The
validity of the PK ⁄PD targets was subsequently
tested using in-vitro PK ⁄PD models, in-vivo
animal models (see Craig, this issue) and ulti-
mately in the clinical setting (see Garau, this
issue).
In developing antimicrobial agents that remain
effective in an environment of increasing resist-
ance, the relationship between PK ⁄PD and drug
performance should be taken into account.
PK ⁄PD is now integral to both drug development
and the evaluation of existing agents [20,21].
CONCLUSION
In summary, antimicrobial resistance among RTI
pathogens, particularly S. pneumoniae, is of
increasing concern world-wide. Various recom-
mendations have been made to limit the develop-
ment and spread of resistance, most notably to
highlight the role of prudent prescribing and the
development of new, more effective agents to
combat resistant pathogens. Those involved in
new drug development are faced with three
challenges—the cost and time required to identify
and evaluate new agents, the potential for
New agents from
new classes
New agents from
existing classes
New formulations
of existing classes
Unknown Same as other
agents in class? Known
Potential for
emergence?
Would need to
overcome
resistance
Would need to
overcome
existing resistance
Option
Safety
Resistance
Faster development time
Fig. 3. Development options for creating new antimicro-
bial agents.
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unfavourable safety proﬁles and the need to
overcome existing resistance. Developing new
formulations of existing agents has the advantage
of working with a known safety proﬁle, although
any new formulation needs to be capable of
overcoming resistance to existing formulation(s)
of the compound. PK ⁄PD principles can be used to
set performance standards for both the optimisa-
tion of currently available compounds and the
development of new agents as part of a science-
based strategy for appropriate prescribing.
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